Several studies have shown that left ventricular hypertrophy (LVH), detected by echocardiography 1 or the 12-lead electrocardiogram (ECG), 2 is not only a cardinal adaptation to increased hemodynamic load in hypertension, but also a common manifestation of preclinical cardiovascular (CV) disease that strongly predicts CV morbidity and mortality.
additional risk factor for coronary heart disease (CHD). Individuals with a history of hospitalized or treated symptomatic heart failure (HF) or known left ventricular ejection fraction <35% were excluded. Participants (n = 33,357) were randomly assigned to chlorthalidone, amlodipine, or lisinopril and pairwise comparisons of the latter 2 agents to the diuretic were to be undertaken to assess the incidence of outcomes.
All participants gave written informed consent, and all centers obtained institutional review board approval. Follow-up visits were at 1, 3, 6, 9, and 12 months and quarterly thereafter. Goal BP of <140/90 mm Hg was to be achieved by titration of the assigned study drug (step 1) and addition of open-label agents (step 2 or 3) when necessary.
Step 1 drugs were encapsulated and identical in appearance. Dosages were 12.5-25 mg/day for chlorthalidone, 2.5-10 mg/day for amlodipine, and 10-40 mg/day for lisinopril. The choice of step 2 drugs was at the clinician's discretion. Study-supplied open-label drugs were atenolol, reserpine, and clonidine for step 2 and hydralazine for step 3 . Other open-label drugs were permitted if clinically indicated.
For the present post-hoc analysis, patients with pacemaker or left or right ventricular branch block were excluded.
Electrocardiography
ECGs were recorded at clinical sites using standardized procedures at baseline and biannually thereafter until study termination or patient death. Individual ECG tracings were forwarded to the core ECG Reading Center (University of Minnesota, Minneapolis), where cross-sectional and serial coding of multiple variables was performed manually by reviewers blinded to treatment assignment. These readings were obtained from 1994 to 2002. Patients were excluded if they had baseline complete left bundle branch block, complete right bundle branch block, nonspecific intraventricular conduction delay QRS ≥120 ms or pacemaker. 8 Cornell voltage, the sum of R wave amplitude in aVL and S wave amplitude in V 3 , >22 mm in women and >28 mm in men was used to identify LVH. 9 
Endpoints
Follow-up procedures, study endpoints, and ascertainment of events have been described previously. 7, 10 The primary endpoint of the present study was all-cause mortality; and secondary endpoints were CHD, nonfatal myocardial infarction (NFMI), stroke, angina, HF, and peripheral arterial disease.
Statistical analyses
Data are expressed as mean (SD) or as proportions. Differences between groups with and without LVH were assessed by independent samples t tests and contingency tables. To test the hypothesis that LVH during antihypertensive therapy results in more clinical events, independent of antihypertensive treatment type and degree of BP lowering, the effect of baseline ECG LVH on risk of clinical endpoints was analyzed, following all randomized patients with baseline ECG LVH values for endpoints for the entire duration of the study, regardless of protocol violations or discontinuation of study medication. The effect of baseline ECG LVH on the risk of clinical endpoints, expressed as the hazard ratio and its 95% confidence interval was analyzed using multivariable Cox regression models. In these models, Cornell voltage was examined using four separate approaches: as a dichotomous variable for the presence or absence of LVH; as a continuous variable; as quartiles of increasing voltage; and as a dichotomous variable comparing the upper quartile with the lower 3 quartiles. The relationship of clinical outcomes to changing levels of ECG LVH during treatment was assessed using Cox models in which ECG LVH measured during the study was entered as a time-varying covariate. The multivariable models were adjusted to standard baseline covariates of age, treatment group, race, ethnicity; history of diabetes, CHD, smoking, and aspirin use; and measured values of heart rate, body mass index, systolic and diastolic BP, potassium, glucose, (estimated) glomerular filtration rate, total cholesterol, low-density lipoprotein and high-density lipoprotein cholesterol, and triglycerides in a stepwise fashion. Data management and analyses were performed by the ALLHAT study group.
RESULTS

Patient characteristics
Detailed baseline characteristics of ALLHAT participants have been reported previously. Briefly, mean age was 67 years, 53% were male, 25% had a history of CHD, and 36% had a history of diabetes mellitus.
Baseline characteristics of patients with and without baseline ECG LVH are shown in Table 1 . Patients with ECG LVH were older; were more likely to be female, Black, nonsmoker; had a higher systolic and diastolic BP, higher heart rate, higher glucose, higher total, low-density lipoprotein and high-density lipoprotein cholesterol; but had less aspirin use, slightly lower kidney function, potassium, and triglyceride levels.
Changes in ECG LVH
Number of individuals with consecutive ECGs at followup is shown in Table 2 . Cornell voltage characteristics at baseline and years 2, 4, and 6 of the study are presented in Table 3 . At baseline, 1,741 patients had ECG LVH. During the study, there was a progression of Cornell voltage in patients with Cornell voltage LVH and a small decrease in Cornell voltage in patients without Cornell voltage LVH (Table 3) .
Clinical end points
The primary outcome of all-cause mortality occurred in 3,561 patients during 6 years of follow-up; 69.9/1,000 patient-years in patients with LVH and 46.1/1,000 patientyears in patients without LVH. CHD occurred in 2,290 patients, NFMI in 1,084, stroke in 1,168, angina in 2,780, HF in 1,575, and peripheral arterial disease in 841 patients. No outcomes had significant study treatment and Cornell voltage interactions; the test for interaction between study treatment and Cornell voltage on the primary endpoint of mortality was amlodipine/chlorthalidone P = 0.189, lisinopril/chlorthalidone = 0.754.
All-cause mortality. The results of multivariable Cox proportional hazards analyses considering baseline Cornell voltage are summarized in Table 4 . In multivariable analysis adjusting for baseline characteristics, higher baseline Cornell voltage examined as a continuous variable and ECG LVH presence were strongly associated with higher risk of death ( Figure 1) . Furthermore, having a Cornell voltage in the 4 th quartile or the 75 th percentile were associated with higher risk of death compared to the 1 st quartile and the lower than 75 th percentile, respectively. Similar relationships to all-cause mortality were seen when baseline ECG LVH presence and Cornell voltage were replaced with on-treatment measures of Cornell voltage treated as time-dependent variables, with statistically significant associations with allcause mortality (Table 5) .
Coronary heart disease. In multivariable Cox analyses ( (Table 5) .
Heart failure. In multivariable analysis (Table 4) , higher baseline Cornell voltage examined as a continuous variable and ECG LVH presence were strongly associated with higher risk of HF. Furthermore, having a Cornell voltage in the 4 th quartile or the 75 th percentile were associated with higher risk of HF compared to the 1 st quartile and the lower than 75 th percentile, respectively. Similar relationships to HF were seen when baseline ECG LVH presence and Cornell voltage were replaced with on-treatment measures of Cornell voltage treated as time-dependent variables, with statistically significant associations with HF for all analyses (Table 5) .
Peripheral arterial disease. In multivariable analyses, higher baseline Cornell voltage, along with a Cornell voltage in the 4 th quartile or the 75 th percentile, were associated with higher risk of PAD (Table 4) . However, there was no association of baseline Cornell voltage or ECG LVH presence to PAD when baseline ECG LVH presence and Cornell voltage were replaced with on-treatment measures of Cornell voltage treated as time-dependent variables, with no statistically significant associations with PAD for any analyses (Table 5) .
DISCUSSION
This study provides the first evidence; from a large population of hypertensive patients not selected to have LVH at baseline, that both baseline and time-varying ECG LVH as well as higher baseline and time-varying Cornell voltage as a continuing variable are associated with higher rates of morbidity and mortality in a middle aged population of hypertensive patients with stage 1 or 2 hypertension plus an additional risk factor for CHD.
In an echocardiographic LIFE substudy, 11 the presence of ECG LVH by Cornell product and/or Sokolow-Lyon voltage criteria identified patients with hypertension having a greater than 70% likelihood of having echocardiographic LVH as well as those not fulfilling the strict cutoff criteria for echocardiographic LVH but with high normal values of indexed LV mass. Moreover, regression of ECG LVH by Cornell product criteria was associated with greater reductions in LV mass and a higher likelihood of regression of echocardiographic LVH in the LIFE study, 12 suggesting that changes in ECG LVH and echocardiographic LVH are linked.
Previous studies show that ECG LVH regression is associated with lower rates of CV events and mortality. 2, 5, 13, 14 The Framingham Heart Study showed in an observational study with ECG LVH by various criteria 2 that a significant decline in Cornell voltage was associated with lower risk of CV disease, whereas a significant increase in Cornel voltage identified individuals at increased risk of CV disease. As a proof of concept, the LIFE study demonstrated that regression of ECG LVH improved prognosis, independent of improvements in BP during antihypertensive therapy. 5, [15] [16] [17] The LIFE study 5 included hypertensive patients with ECG LVH as a surrogate of increased risk of CV events, whereas the present study included hypertensive patients with an additional risk factor for CHD including; previous (6 > months) myocardial infarction or stroke, LVH demonstrated by ECG or echocardiography, history of type 2 diabetes, current cigarette smoking, low high-density lipoprotein cholesterol or other documented other atherosclerotic CV disease. The use of Cornell voltage and Sokolow-Lyon voltage to select patients in the LIFE study 5 limits the generalizability of these findings which may not be representative of other hypertensive populations. In contrast, only 8% of patients had ECG LVH at baseline in the present study. Despite the different population, the present study detected significant increased rates of CV events and all-cause mortality in patients with baseline ECG LVH and higher Cornell voltage independent of antihypertensive treatment and co-morbidity. Moreover, during antihypertensive treatment persistence or development of ECG LVH was significantly associated with increased rates of CV events and all-cause mortality independent of BP.
In a study of 126 never-treated subjects with essential hypertension, echocardiographic LV hypertrophy predicted complex ventricular arrhythmias independently of age and high nocturnal BP. 18 In the LIFE study, lower in-treatment Cornell voltage-duration product was associated with a lower risk of SCD, death resulting from HF, CV death after 24 hours, and death resulting from other CV causes but not death resulting from non-CV death. 17 Other studies have shown that ECG LVH can lead to scars in the myocardium and thereby create a substrate of electrophysiology disorders and fatal arrhythmias irreversible to antihypertensive treatment. 19 This may in part explain not only why patients with LVH have increased rates of CV mortality and SCD, but also explain why some patients with LVH are less responsive to antihypertensive treatment.
Moderate LVH and some geometrical hypertrophic patterns might be an adaption to the moderate higher afterload and angiotensin concentration in hypertensive patients. However, severe LVH can result in some irreversible inappropriate geometrical hypertrophic pattern of LV which has shown to be associated with increased risk of CV events and all-cause mortality independent of antihypertensive treatment. 20 Compared to the present study, the Heart Outcomes Prevention Evaluation (HOPE) trial had similar prevalence (8.2%) of baseline LVH, 13 and showed in accordance with our findings, that persistence or development of LVH was associated with higher risk of death; and regression of LVH was associated with better outcome. A subanalysis of patients without baseline LVH in the HOPE trial showed that these patients had a lower risk of developing LVH if they received antihypertensive treatment with angiotensin-converting enzyme inhibitor compared to other subgroups in their study. These findings suggest that hypertensive patients with severe LVH at baseline may have too great a burden of myocardial scar or fibrosis and/or developed inappropriate geometrical hypertrophic pattern with little or no effect of antihypertensive treatment on myocardial regression and thereby no improvement of survival.
Limitations of the study
The present study was undertaken in patients selected for the combination of mild to moderate hypertension and an additional risk factor for CHD but without HF and thereby may not be directly applicable to patients with isolated hypertension or patients with more severe hypertension or HF. Also, the absence of information on QRS duration precluded calculation of Cornell voltage-duration product criteria that have been utilized in analyses from the LIFE study. 21 As analyses was only adjusted to baseline and not timevarying BP, we cannot exclude that lower drop in BP caused by treatment resistance or low compliance could have contributed to the increased risk of mortality and morbidity associated with baseline LVH.
In conclusion, the present study extends findings from previous studies showing that higher Cornell voltage, as well as ECG LVH, is an independent risk factor of higher rates of CV events and all-cause mortality, not only in patients know with LVH but also in patients with only mild to moderate hypertension and low prevalence of LVH at baseline.
